Dosage and administration
The drug is administered perorally according to the following schedule:
First 3 days: 1 tablet 6 times daily (every 2 hours) with a parallel reduction of the number of cigarettes smoked. If the result is unsatisfactory, the treatment is discontinued and a new therapy can be resumed after 2-3 months. In case of good effect, the treatment should continue according to the following schedule:
from the 4th to 12th day - 1 tablet every 2,5 hours (5 tablets daily);
from the 13th to 16th day - 1 tablet every 3 hours (4 tablets daily;)
from the 21st to 25th day - 1-2 tablets daily.
Complete discontinuation of smoking must occur by the 5th day of treatment.
The high doses may provoke nausea, vomiting, dizziness, tachycardia and muscle weakness. These effects pass quickly after the dose is decreased. .
The drug should be administered carefully to patients with exacerbated peptic ulcer. After completing the treatment course, the patients should refrain from smoking even one cigarette, in order to obtain a lasting effect. .
Country of Manufacture: Bulgaria
US Domestic shipping is available for this product! Choose Ships from: US size option to get it in 3-7 days to any US address. Dont forget to choose US Domestic Shipping when checking out.Availability: in stock
Back in 1865 Acad. A.Orehov detects and analyzes the chemical cytisine contained in the group of plants known as leguminous and main active ingredient in Tabex®. Cytisine belongs to the group of nicotinic blockers, which are known in the clinical practice as respiratory stimulators. Pharmacological studies of Cytisine in the Department of Pharmacology at the Medical Institute – Sofia started in the 1950s, in which the objective was to create ampoule formula for the needs of the reanimation.
During experimental studies on anaesthetised cats, two famous Bulgarian pharmacologists – prof. Paskov and Dr. Dobrev arrived at the important conclusion that due to the little toxicity of nicotine and mostly because its’ weaker peripheral effect on the circulatory system , Cytisine can be used as a means of quitting smoking as it interacts with the same receptors in the human body that nicotine does.
The funny thing about this story is that half a century ago two heavy smokers-pharmacologists worked on developing the idea how to give people dependent of cigarettes a lighter opportunity to undergo withdrawal syndrome (a condition of a bad mood, irritability, headache, etc.) accompanying quitting while to feel invigorated as Cytisine has a proven antidepressant effect.
In 1962 in Bulgaria Prof. Isaev isolated Cytisine from yellow acacia, imitating an intensive research on the creation of the original medicinal product Tabex®. Following large clinical trials in Bulgaria, Germany, Poland and New Zeland confirmed its effectiveness. It is well known that depressive moods and abstinence syndrome are the most difficult to solve mental conditions that accompany any dependency.
Country of Manufacture: Bulgaria
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease.
- J Etter et al (2006) Cytisine for smoking cessation a literature: review and a meta-analysis https://www.ncbi.nlm.nih.gov/books/NBK72476/
- P Tutka, W Zatonski (2006) Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy https://www.ncbi.nlm.nih.gov/pubmed/17220536
- Thomas et al (2018) The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial https://www.ncbi.nlm.nih.gov/pubmed/30589984
- Zatonski et al (2006) An uncontrolled trial of cytisine (Tabex) for smoking cessation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563682/
- Mineur et al (2007) Cytisine, a partial agonist of high affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959230/
- Etter et al (2008) Cytisine for smoking cessation: a research agenda https://www.ncbi.nlm.nih.gov/pubmed/17825502
- LeSage et al (2008) Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652851/
- Astroug et al (2010) Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984118/
- Rollema et al (2010) Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874855/
- Thompson-Evans et al (2011) Cytisine's potential to be used as a traditional healing method to help indigenous people stop smoking: a qualitative study with Māori https://www.ncbi.nlm.nih.gov/pubmed/21385905
- Walker et al (2011) Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking
- https://www.ncbi.nlm.nih.gov/pubmed/21991893 West et al (2011) Placebo-controlled trial of cytisine for smoking cessation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234196/
- Grebenstein et al (2013) The effects of noncontingent and self-administered cytisine on body weight and meal patterns in male Sprague-Dawley rats https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848509/
- Hajek et al (2013) Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759701/ Pine-Abata et al (2013) A survey of tobacco dependence treatment services in 121 countries https://www.ncbi.nlm.nih.gov/pubmed/23404838
- Leaviss et al (2014) What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation https://www.ncbi.nlm.nih.gov/pubmed/24831822
- Walker et al (2014) Cytisine versus nicotine for smoking cessation https://www.ncbi.nlm.nih.gov/pubmed/25517706
- Leaviss et al (2014) What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation https://www.ncbi.nlm.nih.gov/books/NBK262001/
- Dogar et al (2018) The safety, effectiveness and cost‐effectiveness of cytisine in achieving six‐month continuous smoking abstinence in tuberculosis patients—protocol for a double‐blind, placebo‐controlled randomized trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099220/
- Walker et al (2019) Cytisine versus varenicline for smoking cessation for Māori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial https://www.ncbi.nlm.nih.gov/pubmed/30276931